SpringWorks teams with Dana-Farber to test BCMA combo; VBL restarts PhIII trial after FDA clears gene therapy batches
SpringWorks Therapeutics has a new research partner.
The Connecticut biopharma announced today that it has started a research collaboration with the Dana-Farber Cancer Institute in Boston, MA. The collaboration is designed to further investigate nirogacestat, SpringWorks’ investigational gamma secretase inhibitor in conjunction with a variety of anti-BCMA agents. Constantine Mitsiades with the Harvard Medical School will serve as the principal investigator for the research.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.